News >

Encequidar Plus Oral Paclitaxel Increases Response Over IV Paclitaxel in Breast Cancer

Jason M. Broderick @jasoncology
Published: Wednesday, Aug 07, 2019

Rudolf Kwan, MBBS, MRCP, chief medical officer of Athenex, the manufacturer of encequidar

Rudolf Kwan, MBBS, MRCP

The combination of encequidar and oral paclitaxel (Oral Paclitaxel regimen) improved the overall response rate (ORR) compared with IV paclitaxel in patients with metastatic breast cancer, meeting the primary endpoint of a pivotal phase III trial.

“Adding to this potential are the favorable safety data from this study showing lower incidence of neuropathy, which is currently a major reason for discontinuing IV paclitaxel treatment. There is a potential for Oral Paclitaxel, which is not designed to require steroid premedication for immunosuppression, to serve as a cornerstone in chemotherapy in combination with other small molecule anticancer drugs, biologics, and immuno-oncology treatment approaches, including other drug candidates in our oncology pipeline,” added Lau.
Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer. Athenex, Inc. Published August 7, 2019. Accessed August 7, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication